#Autoinjectors Market Industry

[roots07123]

Prefilled Syringes Market Research is Expecting to Accrue Strong Growth in Forecast to 2035

The global prefilled syringes market size is estimated to grow from USD 3.02 billion in 2024 to USD 4.97 billion by 2035, representing a CAGR of 4.6% during the forecast period till 2035.

With the increasing population, the incidence rates of various chronic diseases, such as diabetes, autoimmune disorders, cardiovascular disorders and oncological disorders, are witnessing an upward trend. Various conditions require regular and long-term medications, driving a demand for reliable drug delivery systems. Further, non-adherence to prescribed medication regimen is one of the major factors that not only causes negative implications on the patient’s health, but also adds to the overall pharmaceutical industry’s burden. According to an article published by Contract Pharma in April 2022, non-adherence to prescribed medicines is estimated to cost more than USD 250 billion annually to the drug developers.

As a result, drug delivery devices have undergone significant advancements in the recent years, providing various options to administer a myriad of drugs (catering to different indications) with accuracy and ease. Among the various innovations, prefilled syringes have gained prominence in the healthcare domain as they offer various advantages, including simplified drug administration process (as there is no need for manual filling of drugs), decreased dosing errors (as the syringe is preloaded with precise medication), reduced risk of contamination (as the prefilled syringes are sealed) and enhanced patient adherence (as they can be readily administered in home settings).

Notably, the prefilled syringes domain has witnessed some innovations, that have been mentioned below:

Needle Safety Features: Needle safety mechanisms such as shielded needles or retractable needles have been incorporated to prevent needle stick injuries and improve safety of the devices.

Integration of Autoinjectors: Autoinjectors have been incorporated with prefilled syringes to offer user friendly and automated drug administration.

Dual Chamber Prefilled Syringes: These syringes allow mixing to two different drugs, such as lyophilized drugs and diluents, just prior to their administration

Flush Syringes: These syringes are designed for flushing vascular access devices, such as catheters and intravenous lines

Prefilled Syringes Market Landscape

The current market landscape features the presence of close to 125 prefilled syringes that are currently available / under development for the delivery of different types of medications. The prefilled syringes market is highly fragmented, featuring the presence of established companies, as well as emerging start-ups. Majority of the companies engaged in this domain are headquartered in Asia-Pacific; of these, over 40% are based India.

Notably, players engaged in this domain are shifting their focus towards the development of plastic prefilled syringes; this can be attributed to the various advantages offered by these syringes, including breakage resistance, light-weight, economical manufacturing and decreased risk of contamination. Further, over 5% of the syringes are available in both glass as well as plastic barrel format.

Most of the prefilled syringes are being developed with luer needle system; these syringes have  threaded rims provides a unique locking system, thereby, preventing the needle from being pulled off by the syringe body inadvertently. Further, prefilled syringes are developed in different volume formats, considering the preferences and needs of the customers.

Innovative Pairing: Prefilled Syringe combination products shaping healthcare

During our research, we identified over 120 drugs that have received approval to be used in combination with prefilled syringes, during the period 2013-2023 (till October) and over 50 drugs that are currently being developed in combination with prefilled syringes.

Majority of the drugs being evaluated in late stages of development (phase I/II or phase III) are targeting autoimmune disorders. It is worth mentioning that subcutaneous route is the most preferred route for drug administration by these combination products due to reduced pain and discomfort, convenient self-administration and stable drug absorption.

To know more about the report, visit @

Thank you for reading our report. To know more about the customization feature, please get in touch with us, and our team will ensure the report is customized to meet your requirements.   

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture catalysts, and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports we provide are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serving our clients in the best possible way.

Contact Details

Roots Analysis 

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

Gaurav.chaudhary@rootsanalysis.com 

Website: https://www.rootsanalysis.com/

[harshnews]

Medication Delivery Systems Market Size, Share, Key Drivers, Trends, Challenges and Competitive Analysis

"Global Medication Delivery Systems Market – Industry Trends and Forecast to 2028

Global Medication Delivery Systems Market, By Type (Oral Drug Delivery System, Injection- Based Drug Delivery System, Inhalation/ Pulmonary Drug Delivery System, Transdermal Drug Delivery System, Trans Mucosal Drug Delivery System, Carrier- Based Drug Delivery System, Other Types), Technology (Prodrug, Implants and Intrauterine Devices, Targeted Drug Delivery, Polymeric Drug Delivery, Other Technologies), Carrier Type (Liposomes, Nanoparticles, Microspheres, Monoclonal Antibodies, Others), Application (Cardiovascular Diseases, Oncology, Urology, Diabetes, CNS, Ophthalmology, Inflammatory Diseases Infections, Other Applications), End-Users (Hospitals, Specialized Clinics, Clinical Research & Development Centers), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2028

Access Full 350 Pages PDF Report @

The global Medication Delivery Systems Market is witnessing significant growth due to factors such as the increasing prevalence of chronic diseases, rising demand for self-administration devices, technological advancements in drug delivery systems, and the growing elderly population. The market is expected to showcase lucrative opportunities in the coming years, driven by the need for personalized and targeted drug delivery solutions, integration of digital health technologies, and the rising adoption of injectable biologics and biosimilars in healthcare practices. Moreover, the COVID-19 pandemic has further emphasized the importance of efficient medication delivery systems to ensure timely and accurate administration of therapies.

**Segments**

- By System Type: Prefilled syringes, autoinjectors, wearable injectors, injectable pens, infusion pumps, nasal sprays, nebulizers, and others. - By Application: Diabetes, oncology, autoimmune diseases, cardiovascular disorders, respiratory diseases, and others. - By End User: Hospitals & clinics, home care settings, ambulatory surgical centers, and others.

Considering the market players in the Medication Delivery Systems Market, several leading companies are actively participating in product innovation and strategic collaborations to strengthen their market position and cater to the evolving needs of healthcare providers and patients.

**Market Players**

- Becton, Dickinson and Company - Baxter International Inc. - Pfizer Inc. - Novartis AG - Gerresheimer AG - Johnson & Johnson Services, Inc. - GlaxoSmithKline plc - Novo Nordisk A/S - 3M - F. Hoffmann-La Roche Ltd

In conclusion, the Medication Delivery Systems Market is poised for substantial growth, fueled by the increasing demand for advanced drug delivery technologies, the rising burden of chronic diseases, and the shift towards patient-centric healthcare solutions. Market players are focusing on research and development initiatives to introduce innovative products and gain a competitive edge in the industry. With the integration of digital health solutions and emphasis on personalized medicine, the market is expectedThe Medication Delivery Systems market is experiencing remarkable growth, driven by various factors contributing to the expanding demand for efficient drug administration solutions. The surge in chronic diseases worldwide, coupled with the increasing elderly population, has necessitated the development of advanced medication delivery systems to ensure effective treatment outcomes. Moreover, the rising preference for self-administration devices and the advent of innovative technologies in drug delivery mechanisms have revolutionized the healthcare sector. The market is anticipated to witness significant opportunities in the foreseeable future, driven by the need for personalized drug delivery solutions and the integration of digital health technologies into medical practices.

Segmentation of the Medication Delivery Systems market based on system type includes prefilled syringes, autoinjectors, wearable injectors, injectable pens, infusion pumps, nasal sprays, nebulizers, among others. These diverse system types cater to a wide range of medical applications such as diabetes, oncology, autoimmune diseases, cardiovascular disorders, and respiratory conditions, among others. The market is also segmented by end-users, including hospitals & clinics, home care settings, and ambulatory surgical centers, reflecting the various settings where these medication delivery systems are utilized.

Key market players in the Medication Delivery Systems industry, such as Becton, Dickinson and Company, Pfizer Inc., Novartis AG, and Johnson & Johnson Services, Inc., are actively engaged in product innovations and strategic collaborations to enhance their market presence and meet the evolving needs of healthcare providers and patients. These companies are focusing on research and development efforts to introduce cutting-edge products that ensure efficient drug delivery and improve patient outcomes. The market landscape is characterized by intense competition, prompting companies to differentiate themselves through technological advancements and enhanced product offerings.

In conclusion, the Medication Delivery Systems market is set for substantial growth in the coming years, driven by the increasing demand for advanced drug delivery technologies and the escalating burden of chronic ailments globally. The industry's focus on patient-centric healthcare solutions, coupled with the integration of digital health solutions, is expected to propel market**Global Medication Delivery Systems Market**

- **Type:** Includes Oral Drug Delivery System, Injection-Based Drug Delivery System, Inhalation/Pulmonary Drug Delivery System, Transdermal Drug Delivery System, Transmucosal Drug Delivery System, Carrier-Based Drug Delivery System, and Other Types. - **Technology:** Encompasses Prodrug, Implants and Intrauterine Devices, Targeted Drug Delivery, Polymeric Drug Delivery, and Other Technologies. - **Carrier Type:** Comprises Liposomes, Nanoparticles, Microspheres, Monoclonal Antibodies, and Others. - **Application:** Targets Cardiovascular Diseases, Oncology, Urology, Diabetes, CNS, Ophthalmology, Inflammatory Diseases, Infections, and Other Applications. - **End-Users:** Includes Hospitals, Specialized Clinics, and Clinical Research & Development Centers.

The Global Medication Delivery Systems Market is witnessing robust growth and is poised for significant advancements in the forecast period. The proliferation of chronic diseases worldwide, coupled with the expanding elderly population, is fueling the demand for efficient drug delivery solutions. Technological innovations are revolutionizing the healthcare sector, with a focus on personalized and targeted drug delivery systems gaining traction. Integrating digital health technologies into medication delivery is a key trend shaping the market landscape, alongside the increasing adoption of injectable biologics and biosimilars in healthcare practices. The impact of the COVID-19 pandemic has underscored the critical need for precise and timely administration

Core Objective of Medication Delivery Systems Market:

Every firm in the Medication Delivery Systems Market has objectives but this market research report focus on the crucial objectives, so you can analysis about competition, future market, new products, and informative data that can raise your sales volume exponentially.

Size of the Medication Delivery Systems Market and growth rate factors.

Important changes in the future Medication Delivery Systems Market.

Top worldwide competitors of the Market.

Scope and product outlook of Medication Delivery Systems Market.

Developing regions with potential growth in the future.

Tough Challenges and risk faced in Market.

Global Medication Delivery Systems-top manufacturers profile and sales statistics.

Highlights of TOC:

Chapter 1: Market overview

Chapter 2: Global Medication Delivery Systems Market

Chapter 3: Regional analysis of the Global Medication Delivery Systems Market industry

Chapter 4: Medication Delivery Systems Market segmentation based on types and applications

Chapter 5: Revenue analysis based on types and applications

Chapter 6: Market share

Chapter 7: Competitive Landscape

Chapter 8: Drivers, Restraints, Challenges, and Opportunities

Chapter 9: Gross Margin and Price Analysis

How the Report Aids Your Business Discretion?

This section of this Market report highlights some of the most relevant factors and growth enablers that collectively ensure a high-end growth spurt

The report unravels details on pronounced share assessments across both country-wise as well as region-based segments

A leading synopsis of market share analysis of dynamic players inclusive of high-end industry veterans

New player entry analysis and their scope of new business models

The report includes strategic recommendations for new business veterans as well as established players seeking novel growth avenues

A detailed consultation services based on historical as well as current timelines to ensure feasible forecast predictions

A thorough evaluation and detailed study of various segments as well as sub-segments across regional and country-specific developments

Details on market estimations, market size, dimensions

A review of market competitors, their high-end product and service portfolios, dynamic trends, as well as technological advances that portray high end growth in this Market

Browse Trending Reports:

Asia Pacific Mainframe Market

Asia Pacific Menstrual Cramps Treatment Market

Europe Commercial Cleaning Equipment Market

Europe Mainframe Market

Europe Quantum Computing Market

Europe Tomatoes Market

Europe Utility Locator Market

India Blood Gas Analyzer Market

Middle East And Africa Commercial Cleaning Equipment Market

Middle East And Africa Neurosurgery Market

Middle East And Africa Sports Medicine Market

Middle East And Africa Vaccines Market

Nigeria Cassava Starch Market

Nigeria Starch Processing Market

North America Menstrual Cramps Treatment Market

North America Neurosurgery Market

West Africa Baby Food Market

Antenna Market

Baby Apparel Market

Cassava Starch Market

Castor Oil Market

Cenospheres Market

Coconut Water Market

Collagen Casings Market

Facility Management Market

Functional Confectionery Market

Hemp Seed Market

Infrared Imaging Market

Instant Noodles Market

Laundry Detergents Market

Menstrual Cramps Treatment Market

Micro And Nano Plc Market

Motorcycle Market

Neurosurgery Market

Nickel Alloy Market

Over The Counter Probiotic Supplements Market

Polycystic Kidney Disease Adpkd Market

Private Label Food And Beverage Market

Recreational Cannabis Market

Tofu And Tempeh Market

Tomatoes Market

Vaccines Market

Varnish Makers Market

Wireless Medical Device Connectivity Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC : +653 1251 975

Email: corporatesales@databridgemarketresearch.com"

[healthcaremarketanalysis]

Prefilled Syringes Market worth $13.1 billion by 2030 driven by Rising Chronic Illness Rates | MarketsandMarkets™

The global Prefilled Syringes Market is expected to grow from USD 7.1 billion in 2024 to USD 13.1 billion by 2030, at a CAGR of 10.8%. Prefilled syringes are a convenient and precise medical device for delivering single doses of medication, reducing drug waste and extending product lifespan. They are increasingly adopted due to rising chronic illnesses, demand for effective drug delivery, and regulatory support for safer injection methods. Commonly used for biologics, vaccines, and other therapeutic products, these syringes enhance patient safety by minimizing errors and improving dosing accuracy. The market is expanding due to the prevalence of chronic diseases and the growing trend towards self-administration. However, challenges such as product recalls and competition from alternative drug delivery methods may impact growth. The market is driven by rising demand for biologics and biosimilars, with glass and single-chamber syringes expected to dominate. North America leads the market due to its advanced healthcare infrastructure and high demand for precise drug delivery solutions. Key players include BD, Gerresheimer AG, SCHOTT, and West Pharmaceutical Services, among others.

Download PDF Brochure:

Prefilled Syringes Market Dynamics

Drivers

· Rising target disease population

· Rapid growth in generic products

· Rising adoption of self-medication and digitalization

· Affordable cost with increased efficiency of prefilled syringes

· Technological advancements

Restraints

· Dearth of prefilled syringes with integrated safety features

Opportunities

· Growing healthcare infrastructure across emerging markets

· Surge of biologics and biosimilars in biopharma industry

· Increasing adoption of wearable drug delivery technologies

Challenges

· Availability of cheaper alternatives

· Challenges associated with manufacturing of prefilled syringes

Key Market Players

Becton, Dickinson and Company (US), Gerresheimer (Germany), SCHOTT AG (Germany), West Pharmaceutical Services, Inc. (US), Baxter International Inc (US), Ompi (Italy), Catalent, Inc. (US), Weigao Group (China), Vetter Pharma International GmbH (Germany), Nipro Corporation (Japan), Elcam Medical (Israel), YPSOMED (Switzerland), Oval Medical Technologies (UK), SHL Medical AG (Switzerland), Terumo (Japan).

Request Sample Pages

North America accounted for the largest market share of the global prefilled syringes industry, by region in the forecast period. The pre-filled syringe market is anticipated to be dominated by the North American region due to a number of factors, including an advanced healthcare infrastructure, a high prevalence of chronic diseases, and a focus on patient safety and technological innovation. Its dominant position in the market is also a result of the region’s well-established pharmaceutical industry and rising demand for practical and precise drug delivery solutions. Furthermore, continued R&D expenditures and favorable regulatory environments in North America contribute to the expansion and use of pre-filled syringes.

Recent Developments

· In October 2018, Becton, Dickinson and Company launched the BD Intevi 1mL two-step disposable autoinjector.

· In July 2020, Becton, Dickinson and Company entered into an partnership with Biomedical Advanced Research and Development Authority (BARDA) (US)

· In July 2018, Becton, Dickinson and Company acquired Teva Medical Inc. (US)

Content Source:

[credenceresearchdotblog]

The Sterile Injectable CDMO Market is projected to grow from USD 11,089.66 million in 2024 to USD 26,208.37 million by 2032, reflecting a compound annual growth rate (CAGR) of 11.35%.The global pharmaceutical landscape is evolving rapidly, and one of the sectors witnessing significant growth is the Sterile Injectable Contract Development and Manufacturing Organization (CDMO) market. This market plays a crucial role in the production of sterile injectables, which are vital for delivering medications directly into the bloodstream, ensuring rapid and effective treatment. The increasing demand for biologics, the rise in chronic diseases, and advancements in drug delivery systems are driving the expansion of this market. This article explores the current trends, challenges, and future prospects of the sterile injectable CDMO market.

Browse the full report at https://www.credenceresearch.com/report/sterile-injectable-cdmo-market

Current Market Trends

1. Rising Demand for Biologics: Biologics, including monoclonal antibodies, vaccines, and gene therapies, are becoming the cornerstone of modern medicine. These complex molecules require sophisticated manufacturing processes, which often necessitate sterile injectable formulations. CDMOs, equipped with the necessary expertise and technology, are increasingly partnering with pharmaceutical companies to meet this demand. The shift towards biologics is a key driver of growth in the sterile injectable CDMO market.

2. Innovation in Drug Delivery Systems: The development of novel drug delivery systems, such as prefilled syringes, autoinjectors, and lyophilized products, is revolutionizing the administration of sterile injectables. These innovations not only improve patient compliance but also enhance the stability and efficacy of the drugs. CDMOs are investing heavily in advanced manufacturing technologies to cater to the evolving needs of the pharmaceutical industry, further boosting the market.

3. Outsourcing Trends: Pharmaceutical companies are increasingly outsourcing their sterile injectable manufacturing to CDMOs. This trend is driven by the need to reduce operational costs, access specialized expertise, and focus on core competencies such as research and development. Outsourcing also provides flexibility in scaling production based on market demand, making it an attractive option for both large and small pharmaceutical firms.

Key Challenges in the Sterile Injectable CDMO Market

1. Regulatory Compliance: The production of sterile injectables is subject to stringent regulatory requirements, including Good Manufacturing Practices (GMP) and quality control standards. CDMOs must ensure compliance with these regulations across different markets, which can be complex and resource-intensive. Any lapses in regulatory adherence can lead to significant financial penalties and damage to reputation.

2. High Operational Costs: Manufacturing sterile injectables is a capital-intensive process, requiring state-of-the-art facilities, specialized equipment, and highly trained personnel. The costs associated with maintaining sterile environments, performing regular quality checks, and managing supply chains are substantial. CDMOs must strike a balance between maintaining high standards and managing operational expenses to remain competitive.

3. Supply Chain Disruptions: The COVID-19 pandemic highlighted the vulnerabilities in global supply chains, affecting the availability of raw materials, components, and finished products. For CDMOs, managing these disruptions while ensuring uninterrupted production of sterile injectables has been a major challenge. Building resilient supply chains and diversifying suppliers are critical strategies to mitigate such risks in the future.

Future Prospects and Opportunities

1. Expansion into Emerging Markets: The sterile injectable CDMO market is poised for expansion into emerging markets, particularly in Asia-Pacific and Latin America. These regions are witnessing increased healthcare spending, improved access to medical services, and a growing prevalence of chronic diseases. CDMOs that establish a presence in these markets can tap into new opportunities and drive growth.

2. Adoption of Advanced Technologies: The integration of advanced technologies, such as single-use systems, continuous manufacturing, and digitalization, is expected to enhance the efficiency and flexibility of sterile injectable production. CDMOs that embrace these innovations can improve their competitive edge, reduce time-to-market, and offer cost-effective solutions to their clients.

3. Strategic Collaborations and Partnerships: Collaboration between pharmaceutical companies and CDMOs is likely to become more strategic in the future. Partnerships that go beyond manufacturing to include co-development, risk-sharing, and joint ventures can create synergies and foster innovation. Such alliances will be instrumental in addressing the complexities of producing next-generation sterile injectables.

Key Player Analysis

TriRx Pharmaceutical Services

Tianjin Hankang Pharmaceutical Biotechnology

Astral SteriTech

Pfizer

Prague Scientific

BioTechnique

Evonik

Flagship Biotech International Pvt. Ltd

Fareva

Brooks Laboratories Limited

Famar

Curida AS

Ethypharm

Biophrama Group

Aurigene Pharmaceutical Services

Abbvie

Temad Co.

C. Rompharm Company SRL

Gensenta Pharmaceuticals

Polfa Tarchomin

Quotient Sciences

Sharp

Mithra CDMO

BirgiMefar Group

Segments:

Based on Manufacturing:

Preclinical Manufacturing

Clinical Manufacturing

Commercial Manufacturing

Based on Services:

Stand-alone Services

Drug Formulation and Development

Aseptic Fillings

Analytical Development

Regulatory Support

Packaging and Assembly Services

Technology Transfer

Supply Chain Management

Quality Control and Assurance

Integrated Services

Based on Drug Type:

Monoclonal Antibodies (mAbs)

Cytokines

Insulin

Peptide Hormones

Vaccines

Immunoglobulins

Blood Factors

Peptide Antibiotics

Others

Based on Organization Size:

Small

Mid-sized

Large

Very Large

Based on End-user:

Pharmaceutical Companies

Biopharmaceutical Companies

Research Institutes

Others

Based on the Geography:

North America

US

Canada

Mexico

Europe

Germany

France

UK

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/sterile-injectable-cdmo-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

Website: www.credenceresearch.com

[tamanna31]

Subcutaneous Drug Delivery Devices Market Size, Share, Growth, Analysis Forecast to 2030

Subcutaneous Drug Delivery Devices Industry Overview

The global subcutaneous drug delivery devices market size was estimated at USD 31.2 billion in 2023 and is projected to grow at a CAGR of 7.5% from 2024 to 2030.

The demand for advanced minimally invasive drug delivery devices has surged due to the increasing prevalence of diabetes and cardiovascular diseases (CVD), along with the rise in biologic drug development. According to the International Diabetes Federation (IDF), the global diabetic population is projected to grow by 48.0% annually from 2017 to 2045. IDF notes a significant increase in diabetes cases in low and middle-income countries compared to developed nations. In addition, the World Heart Federation reports that adults with type 2 diabetes have a heightened risk of developing CVD compared to non-diabetics.

The adoption of drug-device delivery systems for managing chronic diseases like diabetes, cardiovascular diseases, multiple sclerosis, and asthma can significantly alleviate healthcare burdens. According to the International Diabetes Federation (IDF), an estimated 537 million adults aged 20 to 79 had diabetes in 2021, projected to increase to 783 million by 2045. IDF notes that 90% of people with diabetes are at risk of type 2 diabetes.

Gather more insights about the market drivers, restrains and growth of the Subcutaneous Drug Delivery Devices Market

To tackle the increasing diabetes burden, companies are executing strategic initiatives to develop and bring to market prefilled syringes like insulin autoinjectors. For instance, in December 2022, Biocorp received FDA 510(k) clearance for its Mallya device for diabetes treatment. This device also holds CE mark approval in Europe as a Class IIb medical device. These regulatory approvals encourage new entrants to innovate drug-device combination products and broaden their market presence.

The rising elderly population has heightened the need for subcutaneous drug delivery devices for diagnosing and treating various chronic health conditions. Studies indicate that individuals aged 65 and older face increased risks of serious ailments such as heart disease, asthma, respiratory infections, COPD, diabetes, and other disorders, as aging weakens the immune system. Consequently, the growing elderly demographic and its burden of chronic illnesses are driving hospitalization rates. According to two American Heart Association data published in June 2024, researchers predict that by 2050, the prevalence of cardiovascular disease will rise to 15% of the population, up from 11.3% in 2020, excluding individuals with high blood pressure.

Browse through Grand View Research's Medical Devices Industry Research Reports.

The global pediatric ENT market size was estimated at USD 7.19 billion in 2023 and is projected to grow at a CAGR of 5.02% from 2024 to 2030. 

The global dental suction systems market size was valued at USD 515.8 million in 2023 and is projected to grow at a CAGR of 4.7% from 2024 to 2030.

Key Subcutaneous Drug Delivery Devices Company Insights

The competitive scenario in the global market is highly competitive, with key players such as Gerresheimer AG, Medtronic; and Ypsomed AG holding significant positions. The major companies are undertaking various organic as well as inorganic strategies such as new product development, collaborations, acquisitions, mergers, and regional expansion for serving the unmet needs of their customers.

Key Subcutaneous Drug Delivery Devices Companies:

The following are the leading companies in the subcutaneous drug delivery devices market. These companies collectively hold the largest market share and dictate industry trends.

Gerresheimer AG

Medtronic Plc

Ypsomed AG

Elcam Medical Group

Novo Nordisk

Insulet Corporation

Becton, Dickinson and Company

West Pharmaceutical Services, Inc.

PharmaJet

Unilife Corporation

Inolife Sciences

Recent Developments

In February 2024, Novo Nordisk A/S partnered with HemoCue to enhance point-of-care diagnostic testing for children with type 1 diabetes in low- & middle-income nations

In April 2024, Ypsomed and ten23 health are collaborating to commercialize the YpsoDose patch injector. This partnership aims to enhance the development, manufacturing, and distribution of the YpsoDose device, providing an innovative solution for subcutaneous drug delivery. The collaboration leverages both companies' expertise to bring this advanced injection technology to market

In March 2023, Sanofi India received marketing approval for Soliqua, a diabetes drug, in India. Soliqua combines insulin glargine and lixisenatide to improve blood sugar control in adults with type 2 diabetes. This approval allows Sanofi to provide a new treatment option for diabetes patients in the Indian market

In July 2023, Civica, Inc. partnered with Ypsomed to produce and supply an insulin injection pen. This collaboration aims to provide affordable insulin options for diabetes patients, utilizing Ypsomed's expertise in manufacturing pens. Civica plans to offer insulin in both vials and prefilled pens to enhance accessibility and affordability.

Order a free sample PDF of the Subcutaneous Drug Delivery Devices Market Study, published by Grand View Research.

[trendtrackershq]

Top 7 Growth Drivers of the Drug Delivery Devices Market By 2030

Introduction:

The drug delivery devices market is experiencing a significant surge, driven by various factors that are revolutionizing the way medications are administered and enhancing patient outcomes. By 2030, the market is expected to witness unprecedented growth, spurred by advancements in technology, increasing prevalence of chronic diseases, and a shift towards personalized medicine. Here, we delve into the top seven growth drivers that are shaping the future of the drug delivery devices market.

Download Free Sample: https://www.nextmsc.com/drug-delivery-devices-market/request-sample

1. Technological Innovations and Advancements

Technological innovation is at the forefront of the drug delivery devices market's growth. The development of advanced drug delivery systems such as micro-needles, smart pills, and implantable devices is transforming the landscape. These technologies offer improved precision in drug administration, reduce the frequency of doses, and enhance patient compliance. For instance, smart pills equipped with sensors can track medication adherence and provide real-time data to healthcare providers, ensuring effective treatment outcomes. Moreover, the integration of artificial intelligence (AI) and machine learning (ML) in drug delivery devices is enabling personalized treatment regimens, further driving market growth.

2. Rising Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases such as diabetes, cancer, and cardiovascular diseases is a significant growth driver for the drug delivery devices market. Chronic diseases often require long-term treatment and management, necessitating the development of efficient drug delivery systems. For example, insulin pumps for diabetes management and transdermal patches for pain relief in cancer patients are gaining traction. The growing burden of chronic diseases is prompting healthcare providers to adopt innovative drug delivery solutions that enhance patient convenience and adherence to treatment protocols.

3. Growing Geriatric Population

The global population is aging, leading to a higher incidence of age-related diseases and conditions that require regular medication. The elderly population often faces challenges with traditional drug administration methods, such as difficulties in swallowing pills or remembering to take medications. Drug delivery devices that offer ease of use, such as inhalers, nasal sprays, and transdermal patches, are becoming increasingly popular among the geriatric population. This demographic shift is expected to significantly boost the demand for advanced drug delivery devices in the coming years.

Inquire Before Buying: https://www.nextmsc.com/drug-delivery-devices-market/inquire-before-buying

4. Shift Towards Home Healthcare

There is a growing trend towards home healthcare, driven by the need to reduce healthcare costs and the preference for personalized care. Drug delivery devices that can be used in home settings, such as auto-injectors, wearable infusion pumps, and self-administrable inhalers, are witnessing increased adoption. Home healthcare allows patients to manage their conditions more conveniently and reduces the burden on healthcare facilities. This shift is fostering the development and uptake of user-friendly drug delivery devices that empower patients to take control of their treatment.

5. Increased Focus on Biologics and Biosimilars

The pharmaceutical industry's focus is increasingly shifting towards biologics and biosimilars, which require specialized drug delivery systems. Biologics, derived from living organisms, are used to treat a wide range of conditions, including autoimmune diseases and cancers. These complex molecules necessitate innovative delivery methods to ensure stability and efficacy. Drug delivery devices such as pre-filled syringes, autoinjectors, and pen injectors are specifically designed to administer biologics effectively. The growing pipeline of biologics and biosimilars is expected to drive the demand for advanced drug delivery devices.

6. Regulatory Approvals and Reimbursements

Regulatory approvals and favorable reimbursement policies play a crucial role in the growth of the drug delivery devices market. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are increasingly approving innovative drug delivery systems, recognizing their potential to improve patient outcomes. Additionally, reimbursement policies that cover the costs of advanced drug delivery devices encourage their adoption among healthcare providers and patients. These regulatory and financial incentives are critical drivers of market expansion.

7. Strategic Collaborations and Partnerships

Strategic collaborations and partnerships between pharmaceutical companies, technology providers, and healthcare institutions are accelerating the development and commercialization of advanced drug delivery devices. These collaborations enable the pooling of resources, expertise, and technologies, leading to the creation of innovative solutions that address unmet medical needs. For instance, partnerships between drug manufacturers and device developers can result in the co-development of combination products, such as drug-eluting stents and implantable infusion pumps. Such synergistic efforts are propelling the growth of the drug delivery devices market.

Conclusion

The drug delivery devices market is poised for significant growth by 2030, driven by technological advancements, the rising prevalence of chronic diseases, an aging population, the shift towards home healthcare, the focus on biologics and biosimilars, regulatory approvals, and strategic collaborations. As the market evolves, it will continue to revolutionize the administration of medications, enhancing patient outcomes and transforming the healthcare landscape. Stakeholders in the healthcare ecosystem, including pharmaceutical companies, device manufacturers, and healthcare providers, must stay abreast of these growth drivers to capitalize on the emerging opportunities in the drug delivery devices market.

[rajrajni]

Autoinjectors Market: Shaping the Future of Alzheimer's Disease Treatment

[healthcaremarketanalysis]

Global Prefilled Syringes Market worth $8.6 billion by 2025

The size of global prefilled syringes market in terms of revenue was estimated to be worth $5.6 billion in 2020 and is poised to reach $8.6 billion by 2025, growing at a CAGR of 9.0% from 2020 to 2025. The research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.

Download PDF Brochure:

Increasing adoption of self-administered injectable drugs is expected to result in the segment occupying the majority of the industry share

The conventional Prefilled Syringes Market is estimated to have the largest market share by value. Growth of this segment can be attributed to the the advantages offered, such as safe administration, ease of use for both healthcare professionals and end users, reduced risk of contamination of the product, less waste of costly API, ease of manufacturing, improved dosing accuracy, and enhanced product differentiation when compared to vials is expected to drive the market growth.

By type, the safety prefilled syringes segment of prefilled syringes industry, is expected to grow at the highest CAGR during the forecast period

The safety prefilled syringes segment is expected to witness the highest growth during the forecast period primarily due to the rising geriatric population globally and availability of biological therapies for patients with chronic conditions and outsourcing of low-risk medical procedures for chronic patients alleviates some of the pressure on hospitals

Glass prefilled syringes is the largest material segment of the prefilled syringes industry

The glass prefilled syringes segment accounted for the largest share of the global industry in 2019. The large share of this segment is attributed to the significant benefits offered, such as prevention of oxygen and water vapor from interacting with drug compounds, compatibility with different filling machines, and seamless integration into pharmaceutical companies’ PFS operations.

Single-chamber prefilled syringes accounted for the largest share of the prefilled syringes industry, by design

The single-chamber prefilled syringes segment accounted for the largest share of the global industry in 2019. Market growth can largely be attributed to the significant advantages with the use of single-chamber prefilled syringes over vials, such as optimized API use with less overfill, reduced material requirements, less drug waste in clinical trials, and simple storage & disposal. Additionally, increasing adoption of self-administered parenteral drugs due to the increasing prevalence of chronic diseases and benefits offered by prefilled syringes.

Europe is the largest regional market for prefilled syringes

Europe is one of the major revenue-generating regions in the global market. Rising prevalence of chronic diseases, growth of the biologics and biosimilars market, technological advancements, geographical expansion by key manufacturers, aging population, and high adoption of self-injection devices are driving the demand for self-injectable prefilled syringes.  are the major factors driving the growth of the global market in Europe.

Global players operating in the global prefilled syringes market are Becton, Dickinson and Company (US), Gerresheimer (Germany), SCHOTT AG (Germany), West Pharmaceutical Services, Inc. (US), Baxter International Inc (US), Ompi (Italy), Catalent, Inc. (US), Weigao Group (China), Vetter Pharma International GmbH (Germany), Nipro Corporation (Japan), Elcam Medical (Israel), YPSOMED (Switzerland), Oval Medical Technologies (UK), SHL Medical AG (Switzerland), Terumo (Japan).

Recent Developments

In October 2018, Becton, Dickinson and Company launched the BD Intevi 1mL two-step disposable autoinjector.

In July 2020, Becton, Dickinson and Company entered into an partnership with Biomedical Advanced Research and Development Authority (BARDA) (US)

In July 2018, Becton, Dickinson and Company acquired Teva Medical Inc. (US)

[cmr-insights]

Drug-Device Combination Products Market Statistics and Global Analysis Report 2030

The global drug-device combination products market was valued at US$ 123.9 billion in 2022 and is anticipated to reach US$ 190.1 billion by the end of 2030 with a CAGR of 5.5% from 2023 to 2030.

Make The Smart Decision. Download A Free Sample Of Our Report @ https://cognizancemarketresearch.com/request/drug-device-combination-products-market/

Manufacturers of drug-device combination products must seek a Notified Body Opinion before releasing them as integral devices and marketing them as “medicinal products” under Article 117 of the Medical Equipment Regulation. The notifying body assesses compliance with the relevant General Performance and Safety Standards (GSPR) and provides the manufacturer with an NBOP Report for inclusion in the Marketing Authorization Application (MAA).

The market for drug-device combinations is expanding due to the increasing prevalence of chronic diseases and technological advancements. However, there are restrictions and issues associated with these products that could hinder their future growth. The stringent regulatory environment creates a barrier to the global market for drug-device combinations, but collaborations and partnerships among major market players can create opportunities for growth.

Global Drug-Device Combination Products Market Amid COVID-19 Pandemic

The COVID-19 pandemic has affected various sectors of the economy, including the market for drug-device combination products worldwide. Governments implemented strict regulations to curb the spread of the virus, creating obstacles for some markets while providing opportunities for others. Lockdowns and restrictions on movement impacted drug-device combination products’ market dynamics in developed and emerging economies alike. However, all economies have since experienced a slow recovery, leading to a positive impact on the market for drug-device combinations.

Drug delivery devices are expected to play a crucial role in providing effective medical care to COVID-19 patients during the pandemic. For instance, Europe issued new guidelines in April 2021 outlining quality specifications that industries must address in their marketing authorization reports for drug-device combination products used in COVID-19 testing. These guidelines help improve drug-device combination products for COVID-19 testing, stimulating market growth during the pandemic.

Increasing Prevalence of chronic diseases, and adoption of novel drug delivery systems & technological trends to boost Drug-Device Combination Products

The market for innovative drug delivery methods is growing due to the rise in chronic diseases like cancer, diabetes, and respiratory illnesses. Reports show that 537 million adults have diabetes and 643 million will have it by 2030. The market is projected to grow as a result of the increased use of drug delivery combination products for consistent drug delivery, which is expected to be driven by the rise in metabolic illnesses.

The market for drug-device combination products will benefit from technical trends brought on by increasing R&D expenditures and a growing industry focus on innovation, leading to groundbreaking discoveries. This will increase competition as new competitors enter the market.

The prevalence of chronic illnesses and the desire for new approaches to disease treatment are driving the adoption of medical device combination products worldwide. These products benefit patients with significant illnesses like spinal cord injuries, diabetes, rheumatoid arthritis, hepatitis, multiple sclerosis, heart disease, cerebral palsy, and anemia. They offer benefits such as reduced side effects, regulated medication delivery, enhanced patient compliance, and focused drug delivery.

Inhalers, autoinjectors, pre-filled pens, pre-filled nebulizers, pre-filled syringes, and transdermal patches are becoming more common due to their associated advantages, including decreased pain levels, improved patient outcomes, shorter hospital stays, and overall healthcare cost-effectiveness. They also offer benefits such as improved tolerance levels, a simpler dosage regimen, and enhanced symptomatic and pharmacokinetic profiles. Synergistic effects that facilitate multi-target treatment are another advantage, which should boost the market for all these systems and open up room for market expansion.

Industry participants are combining technology for monitoring and tracking medicinal device combination goods. They are launching high-end goods developed with sophisticated active ingredients, formulations, delivery methods, and dosage forms like liposomes, transdermal patches, and peptides. They are also focusing on creating formulations, new classes of biologics, and next-generation goods with high viscosity to provide patients with treatments and solutions that will help them adhere to their therapy better.

Expanding healthcare infrastructure and improvements in drug delivery technologies are anticipated to support market expansion throughout that time. However, the industry is anticipated to be hampered by strict regulatory guidelines, product recalls, and issues related to certain drug-device combinations.

North America to spearhead the Global Drug-Device Combination Products Market

North America is expected to have a significant market share in the drug-device combination products industry due to the region’s strong healthcare infrastructure and the adoption of these goods. This is mainly due to the efforts of well-known firms in the area that carry out extensive new product development operations. One of the potential growth factors for this market is the increasing prevalence of chronic diseases in the region, which creates a clinical urgency to use these products. This, in turn, aids in the expansion of the North American market.

There are several reasons for the growth of the drug-device combination products market in North America. Firstly, the region has a favorable regulatory environment, with regulatory agencies creating clear policies and procedures for the clearance of these therapies. Secondly, major industries are adopting new technologies to develop effective medical equipment. Thirdly, there is intensive new product development activity to meet the people’s demands for treatment. Lastly, there is an increase in investment in the healthcare infrastructure, which is further contributing to North America’s leadership in the drug-device combination products market.

Make The Smart Decision. Download A Free Sample Of Our Report @ https://cognizancemarketresearch.com/request/drug-device-combination-products-market/

Numerous companies in the Drug-Device Combination Products industry are striving to expand their market share and revenue through various growth strategies. Among these companies are Medtronic, Zimmer Biomet, Amgen Inc., Mediprint, Propeller Health, Ypsomed, CosMED Pharmaceutical Co. Ltd., Micron Biomedical, Inc., Findair Sp. z o. o., VAXXAS, MetP Pharma AG, SONCEBOZ, Eitan Medical, Vaxess Technologies Inc., Subcuject Aps, E3D Elcam Drug Delivery Devices, OcuMedic, GlaxoSmithKline plc, Bayer AG, NanoPass, Sensirion AG Switzerland, Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.), Insulet Corporation, TheraJect, Otsuka America Pharmaceutical Inc., Raphas Co. Ltd., and EOFLOW CO., LTD.

[sanemyamen]

Autoinjector Market Analysis, Size, Growth, Competitive Strategies, and Worldwide Demand

Latest Report Available at Advance Market Analytics, “Autoinjector Market” provides pin-point analysis for changing competitive dynamics and a forward looking perspective on different factors driving or restraining industry growth. The global Autoinjector market focuses on encompassing major statistical evidence for the Autoinjector industry as it offers our readers a value addition on guiding them in encountering the obstacles surrounding the market. A comprehensive addition of several factors such as global distribution, manufacturers, market size, and market factors that affect the global contributions are reported in the study. In addition the Autoinjector study also shifts its attention with an in-depth competitive landscape, defined growth opportunities, market share coupled with product type and applications, key companies responsible for the production, and utilized strategies are also marked.

Some key players in the global Autoinjector market are AbbVie Inc. (United States),Mylan (United States),Eli Lilly and Company (United States),Ypsomed (Switzerland),Amgen (United States),Becton, Dickinson, and Company (United States),GlaxoSmithKline plc (United Kingdom),Johnson & Johnson (United States),Teva Pharmaceutical (Israel),Antares Pharma (United States),Merck KGaA (Germany),Bayer AG (Germany)

The autoinjector is a syringe with a spring-charged needle having a pre-charged dosage of drugs. The system triggers and administers a measured dosage of a drug when pressed into the body with a sliding motion. Autoinjectors are widely used for epinephrine self-administration; by migraine sufferers (for immediate pain relief); or for medical and emergency treatments. Auto-injectors provide multiple benefits such as decreasing needle-related phobia disorder, decreasing risks of a needle stuck accidents, ensuring dosage quality continuity, and helping increase effectiveness. This has led to significant growth of the global auto-injector market in the forecast period. What's Trending in Market: Availability of Generic Versions of Autoinjectors

Challenges: Lack of Proper Training for using Autoinjectors

Market Growth Drivers: Increasing Prevalence of Targeted Therapies

Rising Incidence of Anaphylaxis across the Global

Growing Number of Regulatory Approvals

The Global Autoinjector Market segments and Market Data Break Down by Type (Disposable Autoinjectors, Reusable Autoinjectors (Prefilled, and Empty)), Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Diabetes, Anaphylaxis, Others Therapies), Route of Administration (Subcutaneous, Intramuscular), End User (Home Care Settings, Hospitals & Clinics, Ambulatory Care Settings)

Presented By

AMA Research & Media LLP